NCT00370786

Brief Summary

To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Nov 2005

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2005

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

August 30, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 1, 2006

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2007

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed
Last Updated

July 11, 2008

Status Verified

July 1, 2008

Enrollment Period

2 years

First QC Date

August 30, 2006

Last Update Submit

July 9, 2008

Conditions

Choroidal Neovascularization

Keywords

Choroidal neovascularization (CNV)BevacizumabNon AMDHigh myopiaangioid streaksOcular histoplasmosisIdiopathic

Outcome Measures

Primary Outcomes (1)

  • Visual acuity

    6 months

Secondary Outcomes (2)

  • central macular thickness

    6 months

  • leakage in fluorescein angiography

    6 months

Study Arms (1)

1

EXPERIMENTAL
Drug: bevacizumab

Interventions

bevacizumabDRUG
1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Cases with subfoveal or juxtafoveal CNV due to a non-AMD related cause.

You may not qualify if:

  • Evidence of AMD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hamid Ahmadieh, MD

Tehran, Tehran Province, 16666, Iran

Location

MeSH Terms

Conditions

Choroidal NeovascularizationAngioid Streaks

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Choroid DiseasesUveal DiseasesEye DiseasesNeovascularization, PathologicMetaplasiaPathologic ProcessesPathological Conditions, Signs and SymptomsRetinal Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Officials

  • Hamid Ahmadieh, MD

    Ophthalmic Research Center of Shaheed Beheshti Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 30, 2006

First Posted

September 1, 2006

Study Start

November 1, 2005

Primary Completion

November 1, 2007

Study Completion

February 1, 2008

Last Updated

July 11, 2008

Record last verified: 2008-07

Locations

IR(1)